Form 4: Director Alva Emily Peterson Reports Acquisition of Amneal Pharmaceuticals Stock

Director Alva Emily Peterson reports the acquisition of 40,258 shares of Amneal Pharmaceuticals Class A Common Stock on May 5, 2025, through the vesting of restricted stock units.

Summary

• On May 5, 2025, Alva Emily Peterson, a director of Amneal Pharmaceuticals, acquired 40,258 shares of Class A Common Stock.
• This acquisition resulted from the vesting of restricted stock units (RSUs) granted on May 2, 2024.
• Peterson also acquired 34,819 restricted stock units on May 6, 2025, which will vest on the later of the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and the day immediately following the first anniversary of the date of grant.
• Following these transactions, Peterson directly owns 211,029 shares of Class A Common Stock and 34,819 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition through vesting of restricted stock units. While insider ownership is generally viewed positively, this is part of a pre-arranged compensation plan.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These transactions are closely monitored by investors for insights into management's perspective on the company's value and future performance.

Stakeholder Impact

• The increase in insider ownership could be perceived positively by shareholders.

Key Dates

Keywords

Amneal Pharmaceuticals, Director, Alva Emily Peterson, Class A Common Stock, Restricted Stock Units, Beneficial Ownership, Form 4, AMRX